OBLN - Obalon Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.7800
-0.0200 (-1.11%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.8000
Open1.8000
Bid1.7700 x 800
Ask1.8400 x 800
Day's Range1.7299 - 1.8200
52 Week Range1.5200 - 34.0000
Volume166,465
Avg. Volume623,484
Market Cap13.696M
Beta (3Y Monthly)-4.78
PE Ratio (TTM)N/A
EPS (TTM)-8.2360
Earnings DateNov. 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
  • Thomson Reuters StreetEvents

    Edited Transcript of OBLN earnings conference call or presentation 8-Nov-19 2:00pm GMT

    Q3 2019 Obalon Therapeutics Inc Earnings Call

  • GlobeNewswire

    Obalon To Present at Two Upcoming Institutional Investor Conferences

    SAN DIEGO, Nov. 14, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and.

  • Could Obalon Therapeutics, Inc.'s (NASDAQ:OBLN) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Obalon Therapeutics, Inc.'s (NASDAQ:OBLN) Investor Composition Influence The Stock Price?

    The big shareholder groups in Obalon Therapeutics, Inc. (NASDAQ:OBLN) have power over the company. Generally speaking...

  • OBALON THERPTCS (OBLN) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    OBALON THERPTCS (OBLN) Reports Q3 Loss, Misses Revenue Estimates

    OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 82.57% and -84.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Obalon Announces Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 08, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • GlobeNewswire

    Obalon Announces Clinical Data Set to be Featured During the 36th ASMBS Annual Meeting at Obesity Week 2019

    SAN DIEGO, Nov. 05, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Obalon Schedules Third Quarter 2019 Financial Results Conference Call for November 8, 2019 at 9:00 a.m. Eastern Time

    SAN DIEGO, Oct. 31, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • Will OBALON THERPTCS (OBLN) Report Negative Q3 Earnings? What You Should Know
    Zacks

    Will OBALON THERPTCS (OBLN) Report Negative Q3 Earnings? What You Should Know

    OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Obalon Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that William J. Plovanic has been promoted to President and Chief Executive Officer, from his prior position of President and Chief Financial Officer. In conjunction with this change, Nooshin Hussainy, previously Vice President of Finance, has been promoted to the position of Chief Financial Officer. “In his prior role as President and CFO, Bill was instrumental in guiding the Company through its transition, galvanizing a new strategy to leverage our proprietary gastric-balloon weight loss system, and recapitalizing the business to fund the go-forward plan,” said Andy Rasdal, Executive Chairman of the Board of Directors at Obalon.

  • GlobeNewswire

    Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has treated the first patients at its Company-owned weight loss treatment center, the Obalon Center for Weight Loss, in San Diego, California. The Obalon Center for Weight Loss is a medical facility staffed with physicians specializing in weight loss, nutritional counselors to help patients change their eating habits for sustainable weight loss, and other staff to help provide safe and effective treatment with the Obalon Balloon System.

  • GlobeNewswire

    Obalon Announces Repayment of All Long-Term Debt and Regaining of Compliance with NASDAQ Listing Requirement

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that it has retired the remaining $5 million of its long-term debt facility with Pacific Western Bank. “We are pleased to continue to transform the Company’s financial position and believe that with no long-term debt and our current cash position we are well-positioned to drive our strategy to bring the Obalon Balloon System to patients in need of a proven weight loss solution,” said William J. Plovanic, President and Chief Financial Officer of Obalon.

  • GlobeNewswire

    Obalon Engages Helmuth T. Billy, MD as Medical Director for its First Company-Owned Weight Loss Treatment Center

    Leading bariatric surgeon and authority in the field to oversee medical activities for the Obalon Center for Weight Loss located in San Diego, CA. SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss announces that it has engaged Helmuth T. Billy, MD, as Medical Director to oversee medical affairs for the Company’s first weight loss treatment center.

  • GlobeNewswire

    Obalon Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

    SAN DIEGO, Aug. 05, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Therapeutics Inc. Announces Pricing of $15,000,000 Public Offering

    Obalon Therapeutics Inc. (OBLN) (the “Company”), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced the pricing of an underwritten public offering of (i) 2,015,000 shares of common stock together with common stock warrants (the “common warrants”) to purchase 1,511,250 shares of common stock and (ii) 1,735,000 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 1,301,250 shares of common stock. The shares of common stock (or pre-funded warrants, as applicable) and accompanying common warrants are being sold together at a combined public offering price of $4.00 per share.

  • Thomson Reuters StreetEvents

    Edited Transcript of OBLN earnings conference call or presentation 24-Jul-19 12:30pm GMT

    Q2 2019 Obalon Therapeutics Inc Earnings Call

  • OBALON THERPTCS (OBLN) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    OBALON THERPTCS (OBLN) Reports Q2 Loss, Misses Revenue Estimates

    OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 7.41% and -78.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Obalon Announces Reverse Stock Split Effective Today

    Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has declared a 1-for-10 reverse stock split of the company’s common stock. The reverse stock split will become effective today, July 24, 2019 (the “Effective Date”). The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Global Market.

  • GlobeNewswire

    Obalon Announces Second Quarter 2019 Financial Results

    SAN DIEGO, July 24, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Enters Into Commercial Lease for its First Company-Owned Retail Weight Loss Center

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a commercial lease for its first Company-owned weight loss center. As part of a strategy to increase patient access and utilization of its novel gastric balloon weight loss system, Obalon intends to own and operate a network of retail centers throughout the United States that focus solely on patients wishing to lose weight using the Obalon Balloon System. “We are transitioning the business with the intent to create a network of Obalon retail centers in the United States, where patients can access our novel weight loss treatment in an environment dedicated to a standardized experience and achieve the most successful outcomes,” said Bob MacDonald, Obalon’s Chief Retail Officer.

  • GlobeNewswire

    Obalon Schedules Second Quarter 2019 Financial Results Conference Call for July 24, 2019 at 8:30 a.m. Eastern Time

    SAN DIEGO, July 22, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Obtains Two New U.S. Patents Covering Its Proprietary Intragastric Balloon System

    SAN DIEGO, July 16, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Strengthens Balance Sheet By Raising Additional Capital And Reducing Debt

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has reduced its outstanding debt under a facility with Pacific Western Bank from $20 million to $5 million. Throughout the second quarter of 2019, Obalon raised approximately $8.8 million in gross proceeds through a series of financings including a registered direct equity offering with A.G.P./Alliance Global Partners acting as our financial advisor, the sale of common stock through its equity line of credit with Lincoln Park Capital and an at-the-market (ATM) equity offering through Canaccord Genuity acting as sales agent.

  • GlobeNewswire

    Bariatric Medical Institute of Texas Presents Favorable Study Results for Obalon Balloon Administration Using Navigation Device and Touch Dispenser

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that substantial clinical data from a study conducted with 14 clinical sites was presented at Obesity Weekend in Chicago on Friday, June 21st 2019 by the study co-primary investigator, Michael V. Seger, MD, FACS, FASMBS, Bariatric Surgeon at Bariatric Medical Institute (San Antonio, TX). The co-primary endpoints of the Continuous Obalon Balloon Administration Location Tracking (COBALT) Study were met, with 100% correct decision-making for administering and inflating the Obalon Balloon System using the Navigation device instead of X-ray imaging.

  • GlobeNewswire

    Obalon Appoints Bob MacDonald as Chief Retail Officer

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces the appointment of Bob MacDonald to the newly created position of Chief Retail Officer. In this role, Mr. MacDonald will be primarily responsible for establishing Obalon-owned retail clinics focused on weight loss utilizing the Obalon Balloon System. “Bob’s outstanding experience in developing a successful national chain of aesthetic retail medical clinics for Sono Bello is a natural fit for Obalon, as we implement a retail-focused initiative to bring our proven weight loss solution to more patients,” said William J. Plovanic, Obalon’s President and Chief Financial Officer.